Free tool
FAERS Monitor: Actos
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 021073 or its brand name (Actos, Pioglitazone Hydrochloride). Reports on generic versions are filed under their own applications.
Reports
43,198
Serious
30,844
71% of reports
Hospitalization
11,767
Death reported
4,332
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- bladder cancer8,740
- blood glucose increased3,398
- nausea3,007
- weight decreased2,092
- diarrhoea1,757
- death1,553
- fatigue1,532
- drug ineffective1,513
- vomiting1,495
- dyspnoea1,426
- dizziness1,422
- decreased appetite1,420
- weight increased1,303
- blood glucose decreased1,207
- asthenia1,182
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2004 | 870 |
| 2005 | 1,323 |
| 2006 | 2,362 |
| 2007 | 2,679 |
| 2008 | 1,644 |
| 2009 | 1,880 |
| 2010 | 2,186 |
| 2011 | 3,106 |
| 2012 | 2,039 |
| 2013 | 1,282 |
| 2014 | 1,127 |
| 2015 | 6,601 |
| 2016 | 3,836 |
| 2017 | 1,859 |
| 2018 | 1,860 |
| 2019 | 1,684 |
| 2020 | 1,378 |
| 2021 | 1,090 |
| 2022 | 984 |
| 2023 | 906 |
| 2024 | 952 |
| 2025 | 913 |
| 2026 | 637 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,010,961 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| bladder cancerSignal | 8,740 | 84.7 | 82.9 | 617,172 |
| blood glucose decreasedSignal | 1,207 | 12.5 | 11.8 | 12,499 |
| blood glucose increasedSignal | 3,398 | 8.9 | 8.6 | 23,682 |
| weight decreasedSignal | 2,092 | 3.7 | 3.5 | 4,082 |
| decreased appetiteSignal | 1,420 | 3.0 | 2.8 | 1,887 |
| weight increasedSignal | 1,303 | 2.8 | 2.7 | 1,563 |
| nausea | 3,007 | 1.9 | 1.8 | 1,222 |
| vomiting | 1,495 | 1.5 | 1.5 | 297 |
| asthenia | 1,182 | 1.5 | 1.4 | 221 |
| dizziness | 1,422 | 1.4 | 1.3 | 158 |
| diarrhoea | 1,757 | 1.3 | 1.3 | 145 |
| dyspnoea | 1,426 | 1.2 | 1.2 | 61 |
| fatigue | 1,532 | 1.0 | 0.9 | 3 |
| death | 1,553 | 0.9 | 0.8 | 28 |
| drug ineffective | 1,513 | 0.6 | 0.5 | 562 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.